Novel phosphoramidates with porphine and nitrogenous drug: One-pot synthesis and orientation to cancer cells was written by Wang, Zhi-Wei;Guo, Can-Cheng;Xie, Wen-Zhong;Liu, Chao-Zhou;Xiao, Chun-Guang;Tan, Ze. And the article was included in European Journal of Medicinal Chemistry in 2010.Category: catalyst-ligand The following contents are mentioned in the article:
One-pot synthesis of novel phosphoramidates with porphine and nitrogenous drug was accomplished. In the absence of light, MTT test showed that they killed the BEL-7402 liver cancer cells effectively in vitro. The cell viability studied on normal liver and cancer cells showed that porphine phosphoramidates selectively kill the cancer cells, which was in sharp contrast with the non-porphine containing compound 4-formylphenyl N,N-bis(2-chloroethyl)-phosphoramidate. These results, coupled with the cell uptake test showing that they could differentiate the tumor cells from the normal cells by their selective accumulation in cancer cells, gave strong support to the notion that the introduction of porphine moiety in these mols. was responsible for the effectiveness and cell differentiability of these porphine phosphoramidates. This study involved multiple reactions and reactants, such as 4-(10,15,20-Tri-p-tolylporphyrin-5-yl)phenol (cas: 57412-08-5Category: catalyst-ligand).
4-(10,15,20-Tri-p-tolylporphyrin-5-yl)phenol (cas: 57412-08-5) belongs to catalyst ligands. Attachment of the ligand to the metal may be through a single atom, in which case it is called a monodentate ligand, or through two or more atoms, in which case it is called a didentate or polydentate ligand. It is clear that future advancements in metal complexes and their applications crucially depend on ligand design, whereas the ligand electronic, steric and topological properties provide numerous improvements to the reactivity and selectivity at the metal centers.Category: catalyst-ligand
Referemce:
Metal catalyst and ligand design,
Ligand Template Strategies for Catalyst Encapsulation – NCBI